Sino Biopharm's anlotinib approved for soft tissue sarcoma treatment

Sino Biopharmaceutical Limited (HKEX:1177) announced that its self-developed anlotinib hydrochloride capsules, when combined with chemotherapy, have been approved by China's National Medical Products Administration for the first-line treatment of locally advanced or metastatic soft tissue sarcoma. This is the ninth approved indication for anlotinib in China. The approval is globally the first chemotherapy combination officially approved for this indication. A Phase III clinical study revealed that the treatment group experienced a median progression-free survival of 8.6 months compared to 3.0 months in the control group (HR=0.30, 95% CI 0.21-0.44, P<0.001), alongside a significantly improved objective response rate of 17.8% vs 2.9%. While overall survival data remains immature, the results indicated a trend toward benefit.